Pfizer Inc. (NYSE:PFE) Shares Sold by SFE Investment Counsel

SFE Investment Counsel trimmed its position in Pfizer Inc. (NYSE:PFE) by 5.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 89,065 shares of the biopharmaceutical company’s stock after selling 5,514 shares during the quarter. SFE Investment Counsel’s holdings in Pfizer were worth $2,578,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PFE. Olistico Wealth LLC acquired a new position in shares of Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer during the second quarter worth approximately $29,000. Quarry LP acquired a new position in Pfizer in the second quarter valued at approximately $31,000. Financial Connections Group Inc. purchased a new position in Pfizer in the second quarter valued at approximately $34,000. Finally, ESL Trust Services LLC acquired a new stake in Pfizer during the first quarter worth approximately $37,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE PFE opened at $28.87 on Tuesday. The stock has a fifty day moving average price of $29.08 and a 200 day moving average price of $28.54. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a market cap of $163.60 billion, a PE ratio of -62.76, a P/E/G ratio of 0.99 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter last year, the business earned $0.67 EPS. The business’s revenue was up 2.1% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. Pfizer’s payout ratio is currently -365.21%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Barclays raised their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.